The role of Semaphorin 4D in bone remodeling and cancer metastasis

Konstantinos Lontos, Juraj Adamik, Anastasia Tsagianni, Deborah L. Galson, John Chirgwin, Attaya Suvannasankha

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Semaphorin 4D (Sema4D; CD100) is a transmembrane homodimer 150-kDa glycoprotein member of the Semaphorin family. Semaphorins were first identified as chemorepellants that guide neural axon growth. Sema4D also possesses immune regulatory activity. Recent data suggest other Sema4D functions: inactivation of platelets, stimulation of angiogenesis, and regulation of bone formation. Sema4D is a coupling factor expressed on osteoclasts that inhibits osteoblast differentiation. Blocking Sema4D may, therefore, be anabolic for bone. Sema4D and its receptor Plexin-B1 are commonly dysregulated in cancers, suggesting roles in cancer progression, invasion, tumor angiogenesis, and skeletal metastasis. This review focuses on Sema4D in bone and cancer biology and the molecular pathways involved, particularly Sema4D-Plexin-B1 signaling crosstalk between cancer cells and the bone marrow microenvironment-pertinent areas since a humanized Sema4D-neutralizing antibody is now in early phase clinical trials in cancers and neurological disorders.

Original languageEnglish (US)
Article number322
JournalFrontiers in Endocrinology
Volume9
Issue numberJUL
DOIs
StatePublished - Jun 19 2018

Fingerprint

Bone Neoplasms
Bone Remodeling
Neoplasm Metastasis
Semaphorins
Neoplasms
CD100 antigen
Osteoclasts
Neutralizing Antibodies
Nervous System Diseases
Osteoblasts
Osteogenesis
Axons
Molecular Biology
Glycoproteins
Blood Platelets
Bone Marrow
Clinical Trials
Bone and Bones

Keywords

  • Cancer
  • Osteoblasts
  • Osteoclasts
  • Plexin
  • Plexin-B1
  • Sema4D
  • Semaphorin 4D

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

The role of Semaphorin 4D in bone remodeling and cancer metastasis. / Lontos, Konstantinos; Adamik, Juraj; Tsagianni, Anastasia; Galson, Deborah L.; Chirgwin, John; Suvannasankha, Attaya.

In: Frontiers in Endocrinology, Vol. 9, No. JUL, 322, 19.06.2018.

Research output: Contribution to journalReview article

Lontos, Konstantinos ; Adamik, Juraj ; Tsagianni, Anastasia ; Galson, Deborah L. ; Chirgwin, John ; Suvannasankha, Attaya. / The role of Semaphorin 4D in bone remodeling and cancer metastasis. In: Frontiers in Endocrinology. 2018 ; Vol. 9, No. JUL.
@article{d37c609429334e11a02061c1b9293581,
title = "The role of Semaphorin 4D in bone remodeling and cancer metastasis",
abstract = "Semaphorin 4D (Sema4D; CD100) is a transmembrane homodimer 150-kDa glycoprotein member of the Semaphorin family. Semaphorins were first identified as chemorepellants that guide neural axon growth. Sema4D also possesses immune regulatory activity. Recent data suggest other Sema4D functions: inactivation of platelets, stimulation of angiogenesis, and regulation of bone formation. Sema4D is a coupling factor expressed on osteoclasts that inhibits osteoblast differentiation. Blocking Sema4D may, therefore, be anabolic for bone. Sema4D and its receptor Plexin-B1 are commonly dysregulated in cancers, suggesting roles in cancer progression, invasion, tumor angiogenesis, and skeletal metastasis. This review focuses on Sema4D in bone and cancer biology and the molecular pathways involved, particularly Sema4D-Plexin-B1 signaling crosstalk between cancer cells and the bone marrow microenvironment-pertinent areas since a humanized Sema4D-neutralizing antibody is now in early phase clinical trials in cancers and neurological disorders.",
keywords = "Cancer, Osteoblasts, Osteoclasts, Plexin, Plexin-B1, Sema4D, Semaphorin 4D",
author = "Konstantinos Lontos and Juraj Adamik and Anastasia Tsagianni and Galson, {Deborah L.} and John Chirgwin and Attaya Suvannasankha",
year = "2018",
month = "6",
day = "19",
doi = "10.3389/fendo.2018.00322",
language = "English (US)",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

TY - JOUR

T1 - The role of Semaphorin 4D in bone remodeling and cancer metastasis

AU - Lontos, Konstantinos

AU - Adamik, Juraj

AU - Tsagianni, Anastasia

AU - Galson, Deborah L.

AU - Chirgwin, John

AU - Suvannasankha, Attaya

PY - 2018/6/19

Y1 - 2018/6/19

N2 - Semaphorin 4D (Sema4D; CD100) is a transmembrane homodimer 150-kDa glycoprotein member of the Semaphorin family. Semaphorins were first identified as chemorepellants that guide neural axon growth. Sema4D also possesses immune regulatory activity. Recent data suggest other Sema4D functions: inactivation of platelets, stimulation of angiogenesis, and regulation of bone formation. Sema4D is a coupling factor expressed on osteoclasts that inhibits osteoblast differentiation. Blocking Sema4D may, therefore, be anabolic for bone. Sema4D and its receptor Plexin-B1 are commonly dysregulated in cancers, suggesting roles in cancer progression, invasion, tumor angiogenesis, and skeletal metastasis. This review focuses on Sema4D in bone and cancer biology and the molecular pathways involved, particularly Sema4D-Plexin-B1 signaling crosstalk between cancer cells and the bone marrow microenvironment-pertinent areas since a humanized Sema4D-neutralizing antibody is now in early phase clinical trials in cancers and neurological disorders.

AB - Semaphorin 4D (Sema4D; CD100) is a transmembrane homodimer 150-kDa glycoprotein member of the Semaphorin family. Semaphorins were first identified as chemorepellants that guide neural axon growth. Sema4D also possesses immune regulatory activity. Recent data suggest other Sema4D functions: inactivation of platelets, stimulation of angiogenesis, and regulation of bone formation. Sema4D is a coupling factor expressed on osteoclasts that inhibits osteoblast differentiation. Blocking Sema4D may, therefore, be anabolic for bone. Sema4D and its receptor Plexin-B1 are commonly dysregulated in cancers, suggesting roles in cancer progression, invasion, tumor angiogenesis, and skeletal metastasis. This review focuses on Sema4D in bone and cancer biology and the molecular pathways involved, particularly Sema4D-Plexin-B1 signaling crosstalk between cancer cells and the bone marrow microenvironment-pertinent areas since a humanized Sema4D-neutralizing antibody is now in early phase clinical trials in cancers and neurological disorders.

KW - Cancer

KW - Osteoblasts

KW - Osteoclasts

KW - Plexin

KW - Plexin-B1

KW - Sema4D

KW - Semaphorin 4D

UR - http://www.scopus.com/inward/record.url?scp=85049354298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049354298&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00322

DO - 10.3389/fendo.2018.00322

M3 - Review article

AN - SCOPUS:85049354298

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - JUL

M1 - 322

ER -